ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / FLGT / news
YDES (44) LMRI (53) CSTL (62) BDSX (40) ⌘ Pro Terminal →

Why FLGT Stock dropped -6.45% Today — RQD Quant Desk Flash

$19.29 -6.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.03

Fulgent Genetics Inc. (FLGT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $567.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FLGT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FLGT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Fulgent Genetics Inc. (NASDAQ: FLGT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $19.29 (-6.45% 1D, market cap $567.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FLGT ranks #755 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FLGT compare to YDES and LMRI in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), FLGT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 40.6%, and ROIC of -6.8%. By comparison, YDES (YD Bio Limited) holds a D grade (44/100 RQD, P/E N/A, ROIC -20.0%, cap $420.7M) and LMRI (Lumexa Imaging Holdings Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $1.10B). Among the 5-stock peer group, FLGT leads on earnings multiple (N/A) while FLGT leads on capital efficiency (-6.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FLGT?
▼

Per FLGT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674930), Fulgent Genetics Inc. generated $322.7M in revenue (+13.8% YoY), -$60.5M in net income, and -$124.2M in free cash flow against $1.21B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $19.03 (-1.35%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (5)Whales (8)SEC (7)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
$33 Bull$17 Base$13 Bear
📬 FREE FLGT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FLGT)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY FLGT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (26% of score)

20D Institutional Volume Accumulation (±8.1% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (26% of score)

FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$21.06-3.5% Next Q
Q2 (-2Q)
36
Grade E$20.33+1.8% Next Q
Q3 (-1Q)
34
Grade E$20.70-6.8% Next Q
Current
31
Grade E$19.29-9.4% Hist 90D α
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FLGT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FLGT currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.83) and Max Pain ($20.25) forces dealer call-delta covering toward $32.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FLGT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FLGT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why FLGT Stock dropped -6.45% Today — RQD Quant Desk Flash

Fulgent Genetics Inc. (FLGT) dropped -6.45% to $19.29, trading at 33% of its 52-week range ($13.46 – $31.04). Stretched risk/reward at current multiples (-7% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 33% of its 52-week range ($13.46 – $31.04) with RSI-14 at 48.3 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±8.1% around $19.29 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 40.6% gross margin and $0 annual free cash flow.
Live FLGT Headlines & Catalysts
MARKET WIREStock Traders Daily • 1d ago
Understanding Momentum Shifts in (FLGT)

Stock Traders Daily report covering Fulgent Genetics Inc. (FLGT) market action, institutional positioning, and fundamental catalysts.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FLGT)

  • ✓Walkthrough of FLGT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
FLGT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +27.58%📐 HORIZONTAL RANGE
2026-11-03O $21.68H $21.68L $19.29C $19.29VOL 201.4K
RES: $23.85SUP: $12.55SMA50: $20.83SMA200: $19.30
$23.38$20.88$18.38$15.88$13.37RES $23.85SUP $12.55$19.292026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FLGT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FLGT Butterfly Map → + Track FLGT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +13.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FLGT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FLGT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FLGT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FLGT)

Health Care Rank #755 of 1015 ⚔️ YDES vs FLGT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FLGT vs. YDES, LMRI, CSTL, BDSX)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Fulgent Genetics Inc. (FLGT) ranks #755 by composite RQD confidence (31/100, grade E) and #421 by equity capitalization ($567.4M). Within this direct 5-issuer industry benchmark cohort, FLGT leads on earnings valuation at N/A trailing P/E, while FLGT leads on capital efficiency and profitability with -6.8% ROIC and 40.6% gross margin. CSTL currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with FLGT at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FLGT ACTIVE
Fulgent Genetics Inc.
E 31/100 — 40.6% -6.8% -6.45% $567.4M Benchmark Subject
YDES
YD Bio Limited
D 44/100 — 28.1% -20.0% +0.51% $420.7M /ydes-vs-flgt →
LMRI
Lumexa Imaging Holdings Inc.
D+ 53/100 — — — -2.28% $1.10B /lmri-vs-flgt →
CSTL
Castle Biosciences Inc.
C 62/100 — 79.4% -9.3% -5.97% $1.14B /cstl-vs-flgt →
BDSX
Biodesix Inc.
D- 40/100 — — -35.0% -6.34% $245.4M /bdsx-vs-flgt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001674930 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fulgent Genetics Inc. (FLGT) reported GAAP revenue of $322.7M (+13.8% vs. FY2024 revenue of $283.5M , and +11.6% cumulative change since FY2023) , GAAP net income of -$60.5M, operating cash flow of -$101.6M, and free cash flow of -$124.2M (-545.1% YoY). On the balance sheet, FLGT closed FY2025 with $1.21B in total assets against $0 in total debt (Altman Z-Score: 4.44, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $322.7M -$60.5M -$101.6M -$124.2M $1.21B —
FY2024 (FY) 2024-12-31 $283.5M -$42.7M $21.1M -$19.3M $1.22B —
FY2023 (FY) 2023-12-31 $289.2M -$167.8M $27.0M $27.0M — —

3. FLGT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FLGT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Fulgent Genetics Inc. (NASDAQ: FLGT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $19.29 (-6.45% 1D, market cap $567.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, FLGT ranks #755 in composite RQD confidence.

How does FLGT compare to YDES and LMRI in the Health Care sector?

Within the Health Care sector (Medical Specialities), FLGT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 40.6%, and ROIC of -6.8%. By comparison, YDES (YD Bio Limited) holds a D grade (44/100 RQD, P/E N/A, ROIC -20.0%, cap $420.7M) and LMRI (Lumexa Imaging Holdings Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $1.10B). Among the 5-stock peer group, FLGT leads on earnings multiple (N/A) while FLGT leads on capital efficiency (-6.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FLGT?

Per FLGT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674930), Fulgent Genetics Inc. generated $322.7M in revenue (+13.8% YoY), -$60.5M in net income, and -$124.2M in free cash flow against $1.21B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FLGT trading relative to its 50-day, 200-day, and 52-week technical levels?

FLGT last traded at $19.29 (-6.45% on volume of 339,407 shares), positioning the stock -7.39% below its 50-day simple moving average ($20.83) and -0.05% below its 200-day simple moving average ($19.30). Across its 52-week range of $13.46 to $31.04, FLGT sits at the 33.2% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±8.1% ($17.73 to $20.85).

Direct Sub-Reports: FLGT RQD Cockpit FLGT 12M Forecast FLGT Earnings & Move FLGT Dividends & DRIP FLGT Insiders & 13F FLGT Whale Options FLGT Profit Sankey FLGT News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ SEC XBRL & RQD VERIFIED

FLGT — Fulgent Genetics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Fulgent Genetics Inc. (FLGT) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $19.29 (-6.45% 1D, market capitalization $567.4M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -6.8%, gross margin of 40.6%, operating margin of -28.2%, and free cash flow yield of -20.82%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of 4.44, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Fulgent Genetics Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Medical Specialities industry. Market capitalization is listed at $0.6B. Revenue scale is reported in the SEC financials, with FY 2025 revenue of $322.7M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Fulgent Genetics Inc. (FLGT) reported $322.7M in annual revenue (up from $283.5M in FY2024, +13.8% YoY) and -$60.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($289.2M revenue, -$167.8M net income) through FY2025, FLGT scaled operating cash flow to -$101.6M and free cash flow to -$124.2M, backed by $1.21B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 31/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -20.82% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $13.46 – $31.04 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -28.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), FLGT carries a macro regime beta of 1.00 and gross margin of 40.6%.

  • Key Question #1: Can FLGT sustain or expand its -28.2% operating margin and -6.8% ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $322.7M and free cash flow of -$124.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is FLGT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FLGT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Fulgent Genetics Inc. (FLGT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FLGT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FLGT Bull vs. Bear Conversation Board — What's Your Call at $19.29?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FLGT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FLGT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $26.81 (+30.0%)
📌 Pinned Debate

The Forensic Balance Sheet pillar is comparatively supported by an Altman Z-Score of 4.44 and Debt/Equity of 0.5, indicating limited ne

Here is why I am bullish on FLGT here at $20.62: The Forensic Balance Sheet pillar is comparatively supported by an Altman Z-Score of 4.44 and Debt/Equity of 0.5, indicating limited near-term solvency pressure.. Compare FLGT's -28.2% operating margin and -6.8% ROIC against the rest of Medical Specialities. As long as cash conversion holds up, dips toward $19.59 are getting bought.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical Specialities. If gross margin (40.6%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $16.70 (-19.0%)
Spot @ $20.62

Negative ROIC of -6.8%, FCF yield of -20.82%, and operating losses in all three reported years show the business is not converting capi

Careful chasing FLGT at $20.62. Negative ROIC of -6.8%, FCF yield of -20.82%, and operating losses in all three reported years show the business is not converting capital into cash.. Gross margin is 40.6%, but operating margin is -28.2%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $16.70 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%